Clinical Trial

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment

Name: First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment — clinical trial record (NCT07297654)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FINELAND

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-09.

Trial Details

NCT Number	NCT07297654
Lead Sponsor	National Cancer Center, Korea Collaborators: Asan Medical Center, Seoul National University Hospital, Seoul National University Bundang Hospital, Samsung Medical Center, Hanyang University Guri Hospital
Conditions	Advanced Hepatocellular Carcinoma
Enrollment	50 participants
Start Date	2026-02
Primary Completion	2028-05 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-01-07